English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Simcere Pharma Given OK to Start China Trial of Cancer Drug

Nov. 12, 2012

Simcere Pharma was given SFDA approval to begin clinical trials in China for BD0801, an anti-angiogenesis drug that will be tested as a treatment for cancer. The IND for the molecule was filed in March 2011. Simcere partners with Apexigen, a Californian company that developed a rabbit-based monoclonal antibody platform. Simcere owns China rights to BD0801, which will be the first of Apexigen’s molecules to start human trials.